UBS Maintains Neutral Rating on GSK Amid CEO Strategy Update
UBS has maintained a 'neutral' rating for GlaxoSmithKline (GSK) ahead of its second-quarter results and an upcoming strategy update by new CEO Luke Miels. The bank highlighted the importance of assessing whether Miels can establish a credible path to GSK's 2031 sales target, while also noting potential challenges in key business areas such as respiratory treatments.
Tickers: $GSK